Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Burkitt Lymphoma 17Lymphoma, Large B-Cell, Diffuse 16Lymphoma 16Leukemia, Myeloid, Acute 16Lymphoma, Non-Hodgkin 15Lymphoma, Mantle-Cell 15Lymphoma, Large-Cell, Immunoblastic 15Leukemia, Lymphocytic, Chronic, B-Cell 15Lymphoma, Follicular 14Leukemia 13Neuroblastoma 12Multiple Myeloma 12Lymphoma, B-Cell, Marginal Zone 12Hodgkin Disease 12Myelodysplastic Syndromes 11Leukemia, Myelomonocytic, Chronic 10Breast Neoplasms 10Myeloproliferative Disorders 9Congenital Abnormalities 9Sezary Syndrome 7Ovarian Neoplasms 7Neoplasms, Plasma Cell 7Mycosis Fungoides 7Lymphoma, T-Cell, Cutaneous 7Anemia, Refractory, with Excess of Blasts 7Sarcoma 6Myelodysplastic-Myeloproliferative Diseases 6Leukemia, Myeloid, Chronic-Phase 6Leukemia, Myeloid, Accelerated Phase 6

Interventions

Bortezomib 3filanesib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Lenalidomide 2Dexamethasone 2sargramostim 1montanide ISA 51 1merphos 1liposomal doxorubicin 1ixazomib 1itacitinib 1incomplete Freund's adjuvant 1fludarabine phosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Steroids 1Stem Cell Transplantation 1Sirolimus 1Proteasome Inhibitors 1Methotrexate 1Injections, Subcutaneous 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Plasma Cell × Peripheral Blood Stem Cell Transplantation × Clear all
NCT01163357 2025-03-26

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

City of Hope Medical Center

Phase 1 Completed
18 enrolled
Other hematologic neoplasmPlasma cell

Chromosome 17 deletion, Leukemia, Plasma Cell, Multiple Myeloma

NCT02504359 2020-11-23

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

OHSU Knight Cancer Institute

Phase 1 Completed
11 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡